Restoring Lives
One Story At A Time

We are Assertio — an assertive, energetic, and empathetic pharmaceutical company built around the mission of advancing patient care. Formerly known as Depomed, we have transformed our company with a current focus on three FDA-approved products in our core areas of neurology, orphan, and specialty medicines, as we continue to identify, license, and develop new products that offer enhanced options for patients who may be underserved by existing therapies. More

In the News

August 9, 2019

Assertio Therapeutics Announces Exchange Offer of $200 Million of its Currently Outstanding 2.50% Convertible Notes Due 2021Read More

August 7, 2019

Assertio Therapeutics Announces Strong Second-Quarter 2019 ResultsRead More

July 17, 2019

Assertio Therapeutics to Report Second Quarter 2019 Financial Results After The Close of Markets on Wednesday, August 7, 2019Read More

More News